In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Celgene gets rights to Epizyme’s personalized cancer therapeutics

Executive Summary

Celgene Corp. will work with epigenetics company Epizyme Inc. to discover, develop, and sell new personalized cancer therapeutics based on Epizyme’s work with histone methyltransferase (HMT) inhibitors for genetically defined cancers.
Deal Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Intra-Biotech Deal
    • Includes Royalty or Profit Split Information
    • Includes Equity
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register